Injection time-dependent effect of adult human bone marrow stromal cell transplantation in a rat model of severe traumatic brain injury.
The object of this study is to evaluate the effects of injecting adult human bone marrow stromal cells (hBMSCs) into rats with severe traumatic brain injury in acute phase and to determine more optimal injection timing between day 1 and day 2 postinjury. The lateral fluid percussion injury model was used. Adult hBMSCs were transplanted into hemisphere to injury sites in the corpus callosum ipsilateral on day 1 (n = 12) or day 7 (n = 8) after injury. A control group (n = 7) underwent only a sham operation without stem cell transplantation. Rats in all groups were analyzed by magnetic resonance spectroscopy (MRS), and by using behavioral, rotarod, and Barnes maze tests on day 1, 7, 14, and 42. Another nine randomly designated rats were sacrificed for immunohistochemical staining. Behavioral test scores increased significantly at all time-points after TBI in the day 7-injected group, compared to the others (p=0.008). GFAP staining was lower on day 42 in day 7-injected rats than in those injected on day 1. But no significant inter- or intra-group differences were observed for other tests. The injection of hBMSCs was found to have limited therapeutic potential with respect to neuroprotection after traumatic brain injury. However, because injection on day 7 after TBI produced greater functional improvements in neurobehavioral tests and more effectively suppressed astroglial activation than an injection on post-injury day 1, we cautiously recommend the injection time of day 7 post injury in hBMSCs transplantation in severe TBI, rather than day 1 post injury but further studies on developing hBMSC-based new therapeutic approaches should be warranted for improving neuroprotection in severe TBI.
Department of Rehabilitation Medicine, Jeju National University Hospital, Seoul, South Korea.
Eun Young
EY
Han
Min Ho
MH
Chun
Sang Tae
ST
Kim
Dong-pyo
DP
Lim
D000328:Adult; D053687:Adult Stem Cells / Q000166:cytology*; D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal; D001930:Brain Injuries / Q000473:pathology / Q000628:therapy*; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D003071:Cognition; D004195:Disease Models, Animal; D005260:Female; D005455:Fluorescent Antibody Technique; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006799:Housing, Animal; D006801:Humans; D007267:Injections; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D018782:Maze Learning; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D017628:Microglia / Q000473:pathology; D018696:Neuroprotective Agents; D051381:Rats; D017207:Rats, Sprague-Dawley; D045442:Rotarod Performance Test; D013997:Time Factors
D019208:Brain-Derived Neurotrophic Factor; D005904:Glial Fibrillary Acidic Protein; D018696:Neuroprotective Agents